// App-Quantinova.ai

: Somatostatin Receptor 2 Antagonism Enhances Plasma Glucagon Levels during Insulin-Induced Hypoglycemia in a Rodent Model of Type 2 Diabetes Mellitus

Researchers

Presenter

  • MEHRAN NEJAD-MANSOURI

Principal Investigators

  • PARINAZ ZAREE BAVANI

  • JULIAN AIKEN

  • NINOSCHKA C. DSOUZA

  • EMILY G. HOFFMAN

  • RICHARD LIGGINS

Medical Centers

  • N/A

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

  • Endocrine/metabolic Diseases (ME)

Disease

  • Type 2 diabetes mellitus

  • Type 1 diabetes mellitus

Biomarkers

  • Somatostatin

  • Somatostatin receptor 2A

Drug/Treatment

  • Streptozotocin

  • Somatostatin

  • NovoRapid

  • Intranasal glucagon

Outcome

  • N/A

Study Design

  • Cross Over

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved